They provide ~5-6 doses at the RECONNECT 1.75mg protocol, which fits inside the documented reconstitution stability window for nasal/SC bremelanotide
It was only at the beginning of the 1990s that several reports confirmed a clinical response in diabetic patients
Yamazaki, H., Kunisada, T., Miyamoto, A., Tagaya, H
"By expanding access to the latest GLP-1 medications with upfront, clear pricing, we're making it easier for customers to get the treatments their health care providers prescribe and to stay on those medications because they are delivered reliably directly to patients." How does this platform affect the GLP-1 market
For patients, these cost saving measures can feel frustrating and counterproductive